{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:11:21Z","timestamp":1791288681627,"version":"4.3.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.mayocp.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T18:00:19Z","timestamp":1501956019000},"page":"1359-1367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Botulinum Toxin in Parkinson Disease Tremor"],"prefix":"10.1016","volume":"92","author":[{"given":"Shivam Om","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duarte","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.mayocp.2017.06.010_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.mayocp.2017.06.010_bib2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2014.1397","article-title":"Tremor","volume":"311","author":"Elias","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.010_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.parkreldis.2015.04.019","article-title":"Tremor-related quality of life: a comparison of essential tremor vs. Parkinson's disease patients","volume":"21","author":"Louis","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.010_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2017.06.010_bib5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/mds.23135","article-title":"Parkinson's disease symptoms: the patient's perspective","volume":"25","author":"Politis","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.mayocp.2017.06.010_bib6","first-page":"CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","volume":"2","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.010_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ncl.2014.09.009","article-title":"Treatment strategies in early and advanced Parkinson disease","volume":"33","author":"Ossig","year":"2015","journal-title":"Neurol Clin"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.010_bib8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4065\/mcp.2011.0045","article-title":"Deep brain stimulation: current and future clinical applications","volume":"86","author":"Lyons","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.010_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jnnp.2007.118786","article-title":"Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease","volume":"79","author":"York","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1-2","key":"10.1016\/j.mayocp.2017.06.010_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"issue":"11","key":"10.1016\/j.mayocp.2017.06.010_bib11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1526-4637.2011.01245.x","article-title":"Treatment of refractory pain with botulinum toxins: an evidence-based review","volume":"12","author":"Jabbari","year":"2011","journal-title":"Pain Med"},{"issue":"8","key":"10.1016\/j.mayocp.2017.06.010_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/WNL.41.8.1185","article-title":"Botulinum toxin treatment of tremors","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2017.06.010_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mds.870090604","article-title":"Botulinum toxin A injections for the treatment of hand tremors","volume":"9","author":"Trosch","year":"1994","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.010_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","article-title":"Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients","volume":"53","author":"Pullman","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mayocp.2017.06.010_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5334\/tohm.240","article-title":"Effective management of upper limb Parkinsonian tremor by IncobotulinumtoxinA Injections using SENSOR-based biomechanical patterns","volume":"5","author":"Rahimi","year":"2015","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"7","key":"10.1016\/j.mayocp.2017.06.010_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations","volume":"18","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.mayocp.2017.06.010_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5334\/tohm.116","article-title":"Methodological issues in clinical drug development for essential tremor","author":"Carranza","year":"2012","journal-title":"Tremor Other Hyperkinet Mov (N\u00a0Y)"},{"issue":"1","key":"10.1016\/j.mayocp.2017.06.010_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.61.1.70","article-title":"Quality of life in patients with Parkinson's disease: development of a questionnaire","volume":"61","author":"De Boer","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.mayocp.2017.06.010_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","article-title":"A\u00a0randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor","volume":"56","author":"Brin","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2017.06.010_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor","volume":"11","author":"Jankovic","year":"1996","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.mayocp.2017.06.010_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s100720070049","article-title":"Botulinum toxin treatment for functional disability induced by essential tremor","volume":"21","author":"Pacchetti","year":"2000","journal-title":"Neurol Sci"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617304822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617304822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T04:51:05Z","timestamp":1602651065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617304822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0025619617304822"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum Toxin in Parkinson Disease Tremor","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}